Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug

With the growing prevalence of type 2 diabetes mellitus (T2DM) the possibility of treating it with available drugs is one of the main issues. Although glycemic control and reduction of micro- and macrovascular outcomes remain important aspects of treatment, the main limiting factors are the availabi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nina A. Petunina, Irina A. Kuzina, Ludmila V. Nedosugova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	type 2 diabetes mellitus glycaemic control gliclazide mr phospholipase c effectiveness safety adverse events availability Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/1491da5627b94711b20e2426c61162cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1491da5627b94711b20e2426c61162cf
record_format	dspace
spelling	oai:doaj.org-article:1491da5627b94711b20e2426c61162cf2021-11-14T09:00:23ZCurrent data on the effectiveness of gliclazide and molecular mechanisms of action of the drug2072-03512072-037810.14341/DM12487https://doaj.org/article/1491da5627b94711b20e2426c61162cf2020-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12487https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378With the growing prevalence of type 2 diabetes mellitus (T2DM) the possibility of treating it with available drugs is one of the main issues. Although glycemic control and reduction of micro- and macrovascular outcomes remain important aspects of treatment, the main limiting factors are the availability and cost of oral hypoglycemic agents. Although newer agents, such as sodium -glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists, potentially being valuable for patients with insulin resistance and cardiovascular complications, they are relatively expensive and have limited availability. Second-generation sulfonylureas effectively reduce glycated hemoglobin and contribute to the prevention of micro- and macrovascular complications of T2DM The review substantiates the role of Gliclazide MR as a more affordable drug for the treatment of T2DM, the safety of which has been confirmed by many studies; cardio-and nephroprotective effects are shown, as well as mechanisms for influencing в-cells of the pancreas and extrapancreatic effects through activation of phospholipase C and the G-protein-сoupled-receptors (GPCR) are analyzed. The latest data on the assessment of adverse events of Gliclazide MR are presented in comparison with both other sulfonylureas and glucose-lowering drugs of other classes.Nina A. PetuninaIrina A. KuzinaLudmila V. NedosugovaEndocrinology Research Centrearticletype 2 diabetes mellitusglycaemic controlgliclazide mrphospholipase ceffectivenesssafetyadverse eventsavailabilityNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 4, Pp 357-367 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus glycaemic control gliclazide mr phospholipase c effectiveness safety adverse events availability Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus glycaemic control gliclazide mr phospholipase c effectiveness safety adverse events availability Nutritional diseases. Deficiency diseases RC620-627 Nina A. Petunina Irina A. Kuzina Ludmila V. Nedosugova Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
description	With the growing prevalence of type 2 diabetes mellitus (T2DM) the possibility of treating it with available drugs is one of the main issues. Although glycemic control and reduction of micro- and macrovascular outcomes remain important aspects of treatment, the main limiting factors are the availability and cost of oral hypoglycemic agents. Although newer agents, such as sodium -glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists, potentially being valuable for patients with insulin resistance and cardiovascular complications, they are relatively expensive and have limited availability. Second-generation sulfonylureas effectively reduce glycated hemoglobin and contribute to the prevention of micro- and macrovascular complications of T2DM The review substantiates the role of Gliclazide MR as a more affordable drug for the treatment of T2DM, the safety of which has been confirmed by many studies; cardio-and nephroprotective effects are shown, as well as mechanisms for influencing в-cells of the pancreas and extrapancreatic effects through activation of phospholipase C and the G-protein-сoupled-receptors (GPCR) are analyzed. The latest data on the assessment of adverse events of Gliclazide MR are presented in comparison with both other sulfonylureas and glucose-lowering drugs of other classes.
format	article
author	Nina A. Petunina Irina A. Kuzina Ludmila V. Nedosugova
author_facet	Nina A. Petunina Irina A. Kuzina Ludmila V. Nedosugova
author_sort	Nina A. Petunina
title	Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
title_short	Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
title_full	Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
title_fullStr	Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
title_full_unstemmed	Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
title_sort	current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/1491da5627b94711b20e2426c61162cf
work_keys_str_mv	AT ninaapetunina currentdataontheeffectivenessofgliclazideandmolecularmechanismsofactionofthedrug AT irinaakuzina currentdataontheeffectivenessofgliclazideandmolecularmechanismsofactionofthedrug AT ludmilavnedosugova currentdataontheeffectivenessofgliclazideandmolecularmechanismsofactionofthedrug
_version_	1718429451116609536

Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug

Ejemplares similares